CommercialCoverageMedium impact
08.02.28, Secukinumab (Cosentyx®) for Intravenous Use
Independence Blue Cross·Rheumatology, Dermatology, Gastroenterology·Pharmacy
Effective date
May 27, 2026
We identified it
Jun 19, 2026
Summary
This policy addresses secukinumab (Cosentyx®) for intravenous use coverage under commercial insurance plans. The policy has been reissued with an effective date of May 27, 2026, indicating updated coverage criteria or administrative changes for this specialty biologic medication used primarily for autoimmune conditions.
Action Required
Before May 27, 2026: Billing team should review the full policy document at the provided URL to understand specific coverage changes for secukinumab IV administration. Update prior authorization processes and billing procedures for Cosentyx IV as needed based on the updated policy requirements.